Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non‐erosive reflux disease – a double‐blind, placebo‐controlled study

• Published in: Alimentary pharmacology & therapeutics 2011-02, Vol.33 (3), p.323-332
• Main Authors: Miwa, H., Inoue, K., Ashida, K., Kogawa, T., Nagahara, A., Yoshida, S., Tano, N., Yamazaki, Y., Wada, T., Asaoka, D., Fujita, T., Tanaka, J., Shimatani, T., Manabe, N., Oshima, T., Haruma, K., Azuma, T., Yokoyama, T.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anti-Ulcer Agents - administration & dosage; Benzamides - administration & dosage; Biological and medical sciences; Digestive system; Double-Blind Method; Drug Therapy, Combination; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gastroesophageal Reflux - drug therapy; Gastrointestinal Agents - administration & dosage; Humans; Male; Medical sciences; Middle Aged; Morpholines - administration & dosage; Omeprazole - administration & dosage; Pharmacology. Drug treatments; Proton Pump Inhibitors - administration & dosage; Quality of Life; Severity of Illness Index; Statistics as Topic; Surveys and Questionnaires; Treatment Outcome
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2010.04517.x

Aliment Pharmacol Ther 2011; 33: 323–332 Summary Background  Proton pump inhibitors (PPIs) are less effective in non‐erosive reflux disease (NERD) patients than in reflux oesophagitis patients. Whether the addition of prokinetics to PPIs improves NERD patients’ symptoms remains unknown. Aim  To evaluate the efficacy of mosapride in NERD patients when used with PPI. Methods  A total of 200 NERD patients were randomised to one of two arms: omeprazole (10 mg once daily) plus mosapride citrate (5 mg three times a day) (treatment arm) and omeprazole plus placebo (placebo arm). The primary endpoint was the rate of responders [visual analogue scale (VAS) was zero or